-- Historically, the Company has specialized in developing primary liver cell immortalization technologies to produce cell lines and cell-based assay systems for use in drug discovery. The Company seeks to become an integrated biopharmaceutical company that will use its proprietary cell-based systems and immune system modulation technologies to discover, develop and commercialize new therapeutics itself and with strategic partners.

-- The intellectual property acquired by MCTI in 2005 included 11 provisional and pending patents related to chimeric antibody technology, treatment of Type 1 diabetes, T-cell tolerance, Toll-like receptors, dendritic cells, dsRNA, and immunosuppression.

-- MultiCell's drug candidate MCT-465 is indicated as a prospective anti-viral therapy for the treatment of influenza A infections. In preclinical studies, originally published in the "Journal of Clinical Investigation," MCT-465 reduced pulmonary influenza A H1N1 virus titers by 1,000-fold in mouse models, resulting in barely detectable levels of the virus. The results suggest MCT-465 may also be able to reduce influenza A H5N1 viral load, also known as the "bird flu" or "avian flu" virus.

-- MultiCell has entered into a research agreement with Columbia University Medical Center focused on evaluating certain hexapeptide molecules for efficacy as potential therapies for the treatment of macular degeneration, a common ocular neurodegenerative disease that results in blindness, the development of blind spots and blurred or distorted vision; Age-related macular degeneration, or ARMD, is a major cause of visual impairment and legal blindness in the United States.

For the FULL and detailed comprehensive report .. MultiCell to Host Conference Call to Discuss Recent SEC Form 10-KSB Annual Report and Strategic Initiatives; Senior Officers to Outline Development of Portfolio of Medical and Stem Cell Technologies